Summary & Overview
CPT 0303U: Hypoxic BioChip Adhesion Assay for Sickle Cell Disease
Headline: New CPT code 0303U designates a proprietary lab test for measuring red blood cell adhesion under low-oxygen conditions, supporting sickle cell disease therapy evaluation.
Lead: CPT code 0303U identifies a Proprietary Laboratory Analyses (PLA) test, Hypoxic BioChip Adhesion from BioChip Labs™, which assesses red blood cell adhesion to vascular lining molecules under reduced oxygen using a microfluidic biochip. The test provides targeted biologic data that can inform therapeutic evaluation in sickle cell disease (SCD).
Why it matters: As precision diagnostics expand, PLA codes like 0303U capture manufacturer- or lab-specific assays that offer novel physiologic insights. National payers are increasingly evaluating coverage and payment approaches for such unique diagnostics due to their potential impact on treatment selection and clinical trial enrollment for rare and complex conditions like SCD.
Payers covered: Analysis includes major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: This publication explains what CPT code 0303U represents, its clinical context in SCD assessment, typical laboratory service settings, and which national payers are considered in the analysis. It also summarizes available benchmarks, policy considerations for PLA codes, and the clinical implications of lab-based hypoxic adhesion testing. Data not available in the input will be identified as such where applicable.
Billing Code Overview
CPT code 0303U is a Proprietary Laboratory Analyses (PLA) code specific to a single laboratory test: Hypoxic BioChip Adhesion from BioChip Labs™. Using a whole blood specimen at reduced oxygen levels, the test evaluates adhesion of red blood cells (RBCs) to molecules found in the blood vessel lining using a microfluidic biochip. The analysis is intended to help evaluate potential therapies for sickle cell disease (SCD).
-
Service type: Laboratory diagnostic assay using a microfluidic biochip under hypoxic conditions to assess RBC adhesion
-
Typical site of service: Clinical laboratory or specialized reference laboratory setting where proprietary PLA testing is performed
Clinical & Coding Specifications
Clinical Context
A 28-year-old patient with known sickle cell disease (SCD) is enrolled in a clinical trial comparing new disease-modifying therapies. The clinician orders a hypoxic adhesion assay to evaluate red blood cell (RBC) adhesive properties under reduced oxygen tension using a microfluidic biochip. A whole blood specimen is collected in the outpatient infusion clinic or clinical research unit, handled per manufacturer instructions to preserve physiologic adhesion characteristics, and transported to BioChip Labs™ for the proprietary test. Results inform investigators and treating clinicians about RBC adhesion responses to investigational agents and may be used as a pharmacodynamic biomarker during therapy evaluation. Typical sites of service include hospital outpatient departments, academic medical center research laboratories, specialty hematology clinics, and reference laboratory settings that coordinate specimen transport and reporting. Specimen collection is performed by nursing or phlebotomy staff; the test is performed by the manufacturer/laboratory and reported using PLA code 0303U.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard primary procedure | Not typically appended; indicates no modifier. Use per payer rules when no other modifier applies. |